Physician profile
Gregory John Barone
NPI 1104016187
$432,941.40
in general payments reported to CMS, 2019-2025
22 companies · $66K in 2025
The $66K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $47K · 2021: $34K · 2022: $80K · 2023: $72K · 2024: $71K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $188K · Travel and Lodging: $14K · Food and Beverage: $6,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $188,029.00 |
| Travel and Lodging | $14,185.14 |
| Food and Beverage | $6,209.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $259,140.44 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $135,143.84 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $34,045.05 | 2019-2024 | Farxiga |
| Medtronic Minimed, INC. | $1,811.67 | 2019 | |
| Abbott Laboratories | $1,143.50 | 2022-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $237.31 | 2021-2024 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.46 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $143.18 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Valeritas, INC. | $142.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $114.84 | 2019 | |
| Zealand Pharma US, INC. | $114.83 | 2021 | |
| Mannkind Corporation | $100.38 | 2021 | |
| Companion Medical, INC. | $85.96 | 2020 | |
| Becton, Dickinson and Company | $78.45 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $75.13 | 2019 | |
| Dexcom, INC. | $68.00 | 2021-2024 | Dexcom G6 Transmitter |
| Cequr Corporation | $41.37 | 2023-2024 | Cequr Simplicity |
| Corcept Therapeutics | $36.43 | 2021 | |
| Insulet Corporation | $30.91 | 2024-2025 | Omnipod |
| Ascendis Pharma Endocrinology INC | $28.09 | 2023 | |
| Merck Sharp & Dohme LLC | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Barone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.